Cancer of prostate

Prostate cancer is one of the most commonly diagnosed cancer in males globally. It is a highly heterogeneous condition; it can be aggressive but will more typically develop

...


Read more on Cancer of prostate

 

 

Latest news articles

Added 2 days ago Drug news

FDA approves Xtandi for non-metastatic prostate cancer.- Astellas + Pfizer.

Astellas Pharma and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide), following FDA Priority...

Added 11 days ago Drug news

Study of Sonablate High Intensity Focused Ultrasound shows equivalence to surgery in prostate cancer.- SonaCare Medical.

SonaCare Medical reports 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate High Intensity Focused Ultrasound...

Added 17 days ago Drug news

Results of Phase III PROSPER trial in Xtandi for prostate cancer published in New England Journal of medicine.- Astellas Pharma.

Astellas Pharma announced that results from the pivotal Phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy...

Search all news articles for Cancer of prostate
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Load more

Guidelines

EAU Guidelines on Prostate Cancer

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa).

Added 2 years ago

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...

Added 2 years ago

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index

NICE has not recommended the PROGENSA PCA3 assay and the Prostate Health Index for use in people having investigations for suspected prostate cancer, who have had a negative or inconclusive transrectal ultrasound prostate biopsy.

Added 3 years ago

Search all guidelines for Cancer of prostate
 

Journal articles

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic...

Added 8 days ago

A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.

The purpose of this study was to determine the efficacy of 8 weeks of degarelix for prostate downsizing before interstitial brachytherapy. We also report associated toxicity and the time course of endocrine recovery over the following 12 months.

Added 4 months ago

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.

This study aimed to ascertain the following: 1) the compatibility of degarelix treatment with diabetes and 2) any specific causal associations of degarelix injections with increased blood clotting and antithrombotic therapy requirements.

Added 4 months ago

Search all journal articles for Cancer of prostate
 

Clinical trials

Study of abiraterone acetate plus ADT versus apalatumide versus abiraterone and apalatumide in patients with advanced prostate cancer with non-castrate testosterone levels

Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced...

Added 1 year ago

Olaparib with or without cediranib in treating patients with metastatic hormone-resistant prostate cancer

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with hormone-resistant prostate cancer that has spread to other places in the body.

Added 1 year ago

Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer

PART I - Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer
The goal of this clinical study PART I is to determine impact of radiotherapy treatment in combination with...

Added 1 year ago

Search all clinical trials for Cancer of prostate
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Guidance update: latest NICE guidelines on prostate cancer

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
154.8
Search all CME for Cancer of prostate